GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

Trial Profile

GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Bucindolol (Primary) ; Metoprolol succinate
  • Indications Atrial fibrillation; Atrial flutter; Heart failure
  • Focus Therapeutic Use
  • Acronyms GENETIC-AF
  • Sponsors ARCA biopharma Inc
  • Most Recent Events

    • 16 Aug 2017 According to an ARCA Biopharma media release, enrollment in the phase IIb portion of the trial has been completed. Two-hundred sixty-seven patients were randomized into the trial.
    • 09 Aug 2017 According to an ARCA Biopharma media release, to maintain the integrity of this trial the unblinded statistical data available to the DSMB has not and will not be disclosed to the company, the trial leadership, or the investigators until the trial is complete.
    • 09 Aug 2017 According to an ARCA Biopharma media release, top-line Phase 2B data expected in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top